LIDDS
LIDDS: Reimagining drug delivery (Redeye)

2022-01-18 07:00
In this update, we revisit LIDDS and take a deeper look at the company’s new vision and strategy, and NanoZolid®’s potential. We argue that the platform and the new focus area of immuno-oncology present a large opportunity and that the management has the capabilities and motivation to take advantage of it. We analyse the clinical data, the competition, the industry dynamics and present an updated valuation with a new target price.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

LIDDS - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -